Supernus acquires NV-5138/SPN-820 assets from Navitor; up to $350M in milestones

SUPERNUS PHARMACEUTICALS, INC.

Supernus buys all IP, inventory, and regulatory materials for CNS compound NV-5138 (SPN-820).
Consideration: complete a Phase 2b study plus milestone payments up to $350M tied to development, regulatory, and commercial goals.
No upfront cash; Supernus may stop pursuing milestones if Phase 2b study fails in its sole discretion.
Agreement includes five-year post-closing non-compete and non-solicitation covenants for Navitor parties.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 1.0

SUPERNUS PHARMACEUTICALS, INC. entered into Asset Purchase Agreement with Navitor Pharmaceuticals, Inc., Navitor Pharmaceuticals, LLC valued at up to $350 million (effective 2026-04-01).

Action: entry
Agreement: asset purchase
Counterparty: Navitor Pharmaceuticals, Inc., Navitor Pharmaceuticals, LLC
Value: up to $350 million
Effective: 2026-04-01

Exact text from the filing

On April 1, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Agreement”), together with related ancillary transaction documents, with Navitor Pharmaceuticals, Inc., a Delaware corporation (“Navitor”), Navitor Pharmaceuticals, LLC, a Delaware limited liability company (“Navitor Parent,” and, together with Navitor, the “Sellers”).

View on SEC.gov

Browse all material agreements →

SUPERNUS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-040497

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.